These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 1969772)

  • 61. Systemic and pulmonary vascular effects of selective dopamine receptor blockade and stimulation in lambs.
    Polak MJ; Drummond WH
    Pediatr Res; 1993 Feb; 33(2):181-4. PubMed ID: 8094550
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine.
    Lass NA; Glock D; Goldberg LI
    Circulation; 1988 Nov; 78(5 Pt 1):1310-5. PubMed ID: 2902941
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of intravenous fenoldopam (SK&F 82526-J) on blood pressure in severe hypertension. SK&F Fenoldopam Working Group.
    Cardiovasc Drugs Ther; 1992 Aug; 6(4):445-6. PubMed ID: 1355665
    [No Abstract]   [Full Text] [Related]  

  • 64. Intraocular pressure increases with fenoldopam, but not nitroprusside, in hypertensive humans.
    Elliott WJ; Karnezis TA; Silverman RA; Geanon J; Tripathi RC; Murphy MB
    Clin Pharmacol Ther; 1991 Mar; 49(3):285-93. PubMed ID: 1672512
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Manipulation of dopamine receptors alters hypoxic pulmonary vasoconstriction in isolated perfused rat lungs.
    Polak MJ; Kennedy LA; Drummond WH
    Life Sci; 1992; 51(17):1317-23. PubMed ID: 1357520
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hemodynamic profile of intravenous fenoldopam in patients with hypertensive crisis.
    Bodmann KF; Tröster S; Clemens R; Schuster HP
    Clin Investig; 1993 Dec; 72(1):60-4. PubMed ID: 7907900
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Fenoldopam mesylate versus sodium nitroprusside in the acute management of severe systemic hypertension.
    Pilmer BL; Green JA; Panacek EA; Elliot WJ; Murphy MB; Rutherford W; Nara AR
    J Clin Pharmacol; 1993 Jun; 33(6):549-53. PubMed ID: 8103527
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The effects of intraoperative fenoldopam on renal blood flow and tubular function following suprarenal aortic cross-clamping.
    Miller Q; Peyton BD; Cohn EJ; Holmes GF; Harlin SA; Bird ET; Harre JG; Miller ML; Riley KD; Hogan MB; Taylor A
    Ann Vasc Surg; 2003 Nov; 17(6):656-62. PubMed ID: 14569432
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hemodynamic effects of selective dopamine receptor agonists in the rat and dog.
    Hieble JP; Owen DA; Harvey CA; Blumberg AL; Valocik RE; DeMarinis RM
    Clin Exp Hypertens A; 1987; 9(5-6):889-912. PubMed ID: 2887313
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors.
    Bakris GL; Lass NA; Glock D
    Kidney Int; 1999 Jul; 56(1):206-10. PubMed ID: 10411694
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A retrospective analysis of fenoldopam renal excretion in 65 subjects: evidence for possible intrarenal formation of fenoldopam from its metabolites.
    Ziemniak JA; Boppana VK; Cyronak MJ; Stote RM
    Pharm Res; 1989 Aug; 6(8):702-5. PubMed ID: 2573048
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Interaction study of fenoldopam--digoxin in congestive heart failure.
    Strocchi E; Tartagni F; Malini PL; Valtancoli G; Ambrosioni E; Pasinelli F; Riva E; Fuccella LM
    Eur J Clin Pharmacol; 1989; 37(4):395-7. PubMed ID: 2574674
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Diuresis and natriuresis during continuous dopamine-1 receptor stimulation.
    Hughes JM; Ragsdale NV; Felder RA; Chevalier RL; King B; Carey RM
    Hypertension; 1988 Feb; 11(2 Pt 2):I69-74. PubMed ID: 2894359
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Natriuretic effects of dopamine agonist drugs in models of reduced renal mass.
    Robles RG; Villa E; Andres A; Martinez J; Ruilope LM; Sancho JM
    J Cardiovasc Pharmacol; 1993; 22 Suppl 2():S88-92. PubMed ID: 7508041
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Sodium nitroprusside potentiates the depressor response to the phosphodiesterase inhibitor zaprinast in rats.
    Dundore RL; Pratt PF; Hallenbeck WD; Wassey ML; Silver PJ; Buchholz RA
    Eur J Pharmacol; 1990 Aug; 185(1):91-7. PubMed ID: 1977600
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Renal blood flow changes induced with endothelin-1 and fenoldopam mesylate at quantitative Doppler US: initial results in a canine study.
    Sehgal CM; Arger PH; Silver AC; Patton JA; Saunders HM; Bhattacharyya A; Bell CP
    Radiology; 2001 May; 219(2):419-26. PubMed ID: 11323466
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of dopaminergic drugs on the sympathoadrenal system.
    Damase-Michel C; Montastruc JL; Tran MA
    Hypertens Res; 1995 Jun; 18 Suppl 1():S119-24. PubMed ID: 8529040
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of fenoldopam in dogs with spontaneous renal insufficiency.
    Brooks DP; Goldstein R; Koster PF; DePalma PD; DiCristo M; Karpinski K; Hyneck M
    Eur J Pharmacol; 1990 Aug; 184(1):195-9. PubMed ID: 1976527
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dopamine agonists, a new perspective in cardiovascular therapy?
    Girbes AR; van Veldhuisen DJ; Smit AJ
    Neth J Med; 1991 Aug; 39(1-2):65-71. PubMed ID: 1683693
    [No Abstract]   [Full Text] [Related]  

  • 80. A preliminary study of the dopamine DA1 agonist fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease.
    MacDonald TM; Jeffrey RF; Muir AL; Lee MR
    Eur J Clin Pharmacol; 1990; 38(2):199-201. PubMed ID: 1970961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.